Skip to main content
Clinical Trials/JPRN-jRCT1080222516
JPRN-jRCT1080222516UnknownUnknown

Blopress Tablets specified drug-use survey Hypertension: Survey on patients with metabolic syndrome

TAKEDA PHARMACEUTICAL COMPANY LTD.0 sites15,000 target enrollmentStarted: June 5, 2014Last updated:
Conditions

Trial Snapshot

Phase
Unknown
Sponsor
Enrollment
15,000

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
ot applicable to ot applicable (—)
Sex
All

Inclusion Criteria

  • Hypertensive patients with at least one of the following risk factors:
  • - Waist circumference >= 85 cm for male and >= 90 cm for female
  • - Fasting triglyceride level >= 150 mg/dL
  • - High-density lipoprotein (HDL) cholesterol level < 40 mg/dL
  • - Fasting blood glucose level >= 110 mg/dL
  • - Body-mass index (BMI) >= 25.0
  • *Patients currently taking medications for hypertriglyceridemia, hypo-HDL-cholesterolemia, or diabetes mellitus are also regarded as meeting the criteria for inclusion in the surveillance

Exclusion Criteria

  • Hypertensive patients who meet all of the following conditions ([1] to [3]):
  • [1] Patients receiving continuous therapy with Blopress Tablets
  • [2] Patients aged < 20 years or >= 75 years
  • [3] Patients with a history of cerebrovascular or coronary artery disease within 6 months before the start of the surveillance

Investigators

Sponsor
TAKEDA PHARMACEUTICAL COMPANY LTD.

Similar Trials

Blopress Tablets specified drug-use survey... | Clinical Trial